[18F]GATT-44 for Imaging

This trial tests a new imaging tracer called [18F]GATT-44 to observe its behavior in the body and its binding efficiency to specific targets, particularly the GABA Transporter (GAT-1). The study consists of three parts: assessing the reliability of [18F]GATT-44 in repeated tests, evaluating its target binding, and measuring its distribution in the body. Healthy individuals without significant medical issues or claustrophobia, who can follow study instructions, may be suitable candidates. This trial plays a crucial role in developing improved imaging methods for diagnosing and understanding certain conditions. As an Early Phase 1 trial, this research aims to understand how this new tracer functions in people, offering participants the chance to contribute to groundbreaking imaging advancements.

The trial information does not specify whether you need to stop taking your current medications. However, if you are taking anticoagulants (blood thinners), you cannot participate in the trial.

Research shows that [18F]GATT-44 is a new substance being tested to help visualize certain brain activities. Currently, there is limited information about its safety for people. This trial is in the early stages, focusing on how the body processes the substance and identifying any side effects.

As an imaging substance, similar substances are usually well-tolerated. Studies often examine how the substance moves and acts in the body. Safety concerns might include mild reactions, but serious side effects are rare at this stage. However, because [18F]GATT-44 is still under investigation, solid safety data from past studies is not yet available.

Researchers are excited about [18F]GATT-44 because it offers a new way to visualize and understand the GABA Transporter (GAT-1) in the brain, which could enhance the diagnosis and monitoring of neurological conditions. Unlike current imaging techniques, this novel tracer specifically targets GAT-1, potentially providing clearer and more detailed images of its activity. This can lead to more accurate assessments of brain function and aid in the development of targeted treatments for conditions related to GABA regulation.

Research has shown that [18F]GATT-44 is a promising new tool for brain imaging. It targets GABA Transporter-1 (GAT-1), which controls brain chemicals. In studies, [18F]GATT-44 outperformed similar tools by showing clear images and binding well to its target. It remains stable in the body, with over 75% unchanged after a period, enhancing image quality. This tracer aims to reveal brain activity more clearly, potentially leading to better understanding and treatment of related conditions. These findings encourage its effectiveness in imaging GAT-1 in the brain. Participants in this trial will engage in various study parts, including test/retest, test-blocking, and whole-body imaging, to further evaluate [18F]GATT-44's performance and characteristics.¹³⁴⁶⁷